Upgraded by Zacks from a “sell” rating to a “hold” Prometic Life Scienc Raised to Hold at Zacks (PFSCF) Posted by Max Byerly on Jul 15th, 2015 // No Comments Share on StockTwits Prometic Life Scienc logoPrometic Life Scienc (NASDAQ:PFSCF) was upgraded by Zacks from a sell rating to a hold rating in a research note issued to investors on Wednesday, Marketbeat reports. According to Zacks, ProMetic Life Sciences Inc. is a biopharmaceutical company. The company is involved in bioseparations, plasma-derived therapeutics and small-molecule drug development. Its operating segment consists of Therapeutics and Protein Technology. Therapeutics segment products include PBI-4050 for treatment of fibrosis with chronic kidney diseases, certain cancers and side effects associated with chemotherapy; PBI-4419, an anti-fibrotic and anti-inflammatory compound for kidney injury and chronic kidney diseases and PBI-1402 for the treatment of anemia indications. Protein Technology segment provides plasma protein purification system, bioseparation products and prion capture/pathogen removal technology platform. ProMetic Life Sciences Inc. is headquartered in Laval, Canada. Shares of Prometic Life Sciences(NASDAQ:PFSCF) traded up 0.4013% during mid-day trading on Wednesday, hitting $1.8762. The stock had a trading volume of 30,760 shares. Prometic Life Sciences has a one year low of $1.00 and a one year high of $2.28. The stocks 50-day moving average is $1.86 and its 200-day moving average is $1.87. The companys market cap is $1.08 billion.